Introduction
resected stage IIIB-C, Melanoma, melanoma
DISEASE, MELANOMA, MELANOMA, OF SKIN CANCER
Melanoma is the deadliest form of skin cancer [Given that the prognosis among patients with melanoma is worse with advanced disease stage [Although the efficacy and safety of ipilimumab, pembrolizumab, and dabrafenib plus trametinib have been compared against placebo as adjuvant melanoma treatment in randomized clinical trials [In 2019, Freeman et al. [The current study aimed to assess the RFS of nivolumab versus placebo and ipilimumab and the OS of nivolumab versus placebo over 4 years, as well as the corresponding NNT in patients with resected stage IIIB-C melanoma using pooled data from EORTC 18,071 and CheckMate 238. The analysis of OS was conducted accounting for differences in post-recurrence treatments between the two trials and its impact on OS. Results from this study are of value to patients, clinicians, payers, and other healthcare decision-makers as they could be used to evaluate the long-term clinical value of adjuvant treatment with nivolumab following surgical resection compared with other options, including routine surveillance.